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The aim of this study was to verify through relative survival (an estimate of cancer-specific survival) the true prognostic factors of
colorectal cancer. The study involved 506 patients who underwent locally radical resection. All the clinical, histological and laboratory
parameters were prognostically analysed for both overall and relative survival. This latter was calculated from the expected survival of
the general population with identical age, sex and calendar years of observation. Univariate and multivariate analyses were applied to
the proportional hazards model. Liver metastases, age, lymph node involvement and depth of bowel wall involvement were
independent prognosticators of both overall and relative survival, whereas carcinoembryonic antigen (CEA) was predictive only of
relative survival. Increasing age was unfavourably related to overall survival, but mildly protective with regard to relative survival. Three
out of the five prognostic factors identified are the cornerstones of the current staging systems, and were confirmed as adequate by
the analysis of relative survival. The results regarding age explain the conflicting findings so far obtained from studies considering
overall survival only and advise against the adoption of absolute age limits in therapeutic protocols. Moreover, the prechemotherapy
CEA level showed a high clinical value.
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A large body of investigational data demonstrates that the
prognosis of patients undergoing bowel resection for colorectal
cancer is mainly determined by factors related to local tumour
growth and the presence or absence of nodal and/or distant
metastases. Many classification systems have been devised to
categorise these anatomical factors for clinical use but an
increasing number of new pathological and nonanatomical
elements show interesting correlations with survival and would
be worth testing systematically for selective integration into the
available staging classifications. Improvement of the prognostic
accuracy of these classifications might allow a more flexible use of
the increasing number of new drugs and therapeutic options now
available for postsurgical management of patients with colorectal
cancer. However, since this malignancy is a disease of the elderly
and the populations of developed countries are ageing rapidly,
overall survival, as currently investigated, may not be the most
suitable outcome parameter for evaluating the real prognostic
impact of tumour-linked factors. Because about one-half of all
colorectal carcinomas in our series occur in people aged 65 years
or older, and a considerable number of these subjects die of other
causes with no evidence of cancer, a fraction of these deaths should
not be related to the tumour.
There are two main purposes of the present work: (1) to verify
the prognostic significance of the current clinicopathological
factors through a study of both overall and relative survival, this
latter being a selective estimate of the chance of surviving the
effects of cancer; (2) to include – among the factors to be tested –
the linear dimensions of the resected tumour as an estimate of its
preoperative volume. Tumour size has never shown a clear
prognostic value (Newland et al, 1994; Frank et al, 1995; Takahashi
et al, 1997), but its potential effect has always been evaluated
through overall survival analyses, in which it has shown a
satisfying correlation with carcinoembryonic antigen (CEA) and
carbohydrate antigen 19-9 (CA19-9) levels (Louhimo et al, 2002;
Yuste et al, 2003). Since these markers are commonly considered
of prognostic value (Kanellos et al, 2006a), but are inconstantly
expressed, a re-evaluation of the predictive value of tumour size
through an analysis of relative survival might yield definitive
results on this matter.
PATIENTS AND METHODS
Patients
From 1 January 1994 to 31 December 2002, 536 patients were
referred to the Day Hospital of the Clinica Medica I after local
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sradical resection of colonic carcinoma (n¼324) or rectal
carcinoma (n¼182). These two groups of patients were studied
together since their survival proved to be very similar. During the
time of the study, there was not active clinical research on
colorectal cancer in the Clinica Medica I, and patients were
referred to the Day Hospital from the surgical divisions of the San
Matteo Hospital and from the hospitals in the neighbourhood of
20–30km. The following information was collected for each
patient presenting signs and symptoms, location of the tumour,
description of the surgical operation, radicality of the resection
performed, macroscopic features at presentation, diameters of the
tumour mass, number of regional metastatic lymph nodes,
contiguous viscera involved, number and diameters of distant
metastatic lesions, microscopic subtype of the tumour, depth of
penetration into the bowel wall, cell differentiation, grade of
lymphatic, venous and perineural invasion, metastatisation of the
collected lymph nodes and main laboratory data at the start of
adjuvant chemotherapy and about 5–6 weeks after surgery (blood
cell count, serum protein electrophoresis, liver and kidney
function tests, and serum levels of CEA and CA19-9).
Macroscopic evaluation of the whole resected material and
histological examination of the sampled specimens were per-
formed centrally. Vascular and lymphatic invasions were evaluated
on paraffin sections stained with haematoxylin–eosin; cases in
which recognition of endothelial structures was uncertain under-
went immunohistochemical search for CD34 and CD31 markers. In
fact, both the anti-CD31 antibody, which identifies the antigen ER-
MP12, identical to the vascular endothelial adhesion molecule
PECAM-1, and the anti-CD34 antibody, which stains normal and
endothelial cells, make the identification of vascular and lymphatic
vessels easier. Neural invasion was always evaluated through
haematoxylin–eosin staining.
Carcinoembryonic antigen and CA19-9 were measured after
surgery, before the start of chemotherapy (if any) by two sites,
noncompetitive immune assays performed on an automated
immunochemistry analyzer with chemiluminescence detection
(Advia Centaur, Bayer Diagnostics, Tarrytown, NY, USA). The
measurement ranges for CEA and CA19-9 were 0.5–100ngml
 1
and 1.2–700Uml
 1, respectively; when results exceeded the upper
limit of the analytic range, serum was diluted according to the
manufacturer’s instructions. Quality control was ensured by
assaying three levels of control sera in each analytical series
within a 3-monthly European interlaboratory control programme.
Several patients in the present series were referred postoperatively
to our unit from a neighbouring hospital, often with preoperative
CEA measurements that were not technically comparable or had
not even been assessed.
For the purposes of this study, patients alive in 2005 who had
not had a medical examination within the preceding 6 months
were recalled for a new clinical and instrumental control. The vital
status of those patients who did not respond to this recall was
ascertained by telephone or investigated in the General Registry
Offices of their last known municipality of residence. Thirty
patients were excluded from the study because of incomplete data
regarding either surgical resection or pathological findings. Thus,
506 patients formed the population of the study. All were staged
according to Dukes’ classification (Dukes, 1940), the modified
Astler–Coller classification (Astler and Coller, 1954) and the TNM
classification (American Joint Committee on Cancer, 2002). The
main characteristics of the study population are reported in
Table 1.
Unless there were particular clinical conditions, adjuvant
chemotherapy was administered according to the following
criteria: stages II and III patients were treated with the regimen
proposed by Machover et al (1982) (5-fluorouracil plus folinic
acid, at the doses of 370 and 100mgm
 2, respectively, with daily
i.v. bolus injection for 5 days every 28 days, for six cycles). Until
1998, patients in stage IV were treated with the schedule described
by De Gramont et al (1997) (5-fluorouracil 400mgm
 2 in i.v. bolus
injection and 600mgm
 2 in continuous infusion plus folinic acid
100mgm
 2 in a 2-h infusion for 2 days every 14 days for 12 times),
in six cases also combined with regional intra-arterial 5-fluoro-
uracil infusion for liver metastases. After 1998, patients in stage IV
were administered either infusional fluorouracil or FOLFIRI
(Andre et al, 1999) or FOLFOX 4 regimens (De Gramont et al,
2000) (these last are De Gramont-like schedules with the addition
of either irinotecan 180mgm
 2 or oxaliplatin 85mgm
 2 on the
first day, respectively). Since 2000, 11 patients with liver
metastases were spared locoregional chemotherapy and underwent
radiofrequency thermoablation. Forty-one patients with rectal
carcinoma also received local radiotherapy. Survival of the patients
treated in the last 4 years of the study, when analysed stage by
stage, tended to be better than that of the first quadrennium, but
differences were not statistically significant.
Statistics
The time parameters taken into account were overall survival and
relative survival. This latter was calculated as the ratio of the
overall survival rate observed in the patient population and the
expected survival rate drawn from the general reference population
for subjects similar to the patients with respect to age, sex,
calendar year of initial observation and length of observation
(Armitage and Berry, 1987). The age-, gender-, and calendar year-
specific death rates available from the National Italian Mortality
Tables (ISTAT, Istituto Nazionale di Statistica) were used to
calculate the expected deaths – and so the expected survival. The
age changes according to individual birthdays in every year of the
follow-up were taken into account. In this way, each patient was
considered to have a wide control group from the general
population with corresponding anagraphic characteristics with a
well-defined probability of dying (or surviving). Consequently, the
Table 1 Main clinical and pathological characteristics of the 506 patients of the study (values between parentheses, ranges between brackets)
Sex (male: 292; female: 214) Age (mean¼64.3 years [29–83])
Days from surgery to chemotherapy:
a 42±14 Tumour site (colon: 324; rectum: 182)
Tumour shape (ulcerated: 265; nonulcerated: 241) Tumour size (largest +: 4.8±2.4cm [0.5–18]
Depth of involvement (T1: 11; T2: 31; T3: 400; T4: 64) Histological grading (G1:5 ;G 2: 421; G3: 69; G4: 11)
Angioinvasion (yes: 47; no: 459) Lymphoinvasion (yes: 151; no: 355)
Neuroinvasion (yes: 18; no: 488) Lymphocyte infiltration (yes: 358; no: 148)
Regional node involvement (yes: 263; no: 243) Distant node involvement (yes: 22; not: 484)
Presence of liver metastases (yes: 74; no: 432) Number of liver metastases (median¼1 [1–14]
Extrahepatic metastases (yes: 43; no: 463) Haemoglobin (g per 100ml: 12.1±1.7 [7.6–16.0])
Serum albumin (g per 100ml: 4.02±0.52 [2.60–5.63]) Serum CEA (ngml
 1: mean¼4.3 [0.1–6.000])
Serum CA19-9 (Uml
 1: mean¼9.1 [0.1–11.000]) Dukes’ stages (A: 22; B: 183; C: 176; D: 125)
MAC stages (A: 16; B: 189; C: 176; D: 125) TNM stages (TI: 16; TII: 189; TIII: 176; TIV: 125)
aIn patients who did not undergo chemotherapy, the interval was calculated from surgery to the first clinical follow-up evaluation.
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srelative survival, obtained by adjusting observed survival for
normal life expectancy, can be considered a satisfactory estimate of
the chance of surviving the effects of cancer. In detail, and for
example, the expected probability of death (from mortality tables)
of a man born on 1 August 1926, who survived the whole 1997 is
that of a 70-year-old man during the first 212 days of the year
(0.03063 per 100000) and that of a 71-year-old man in the
remaining 153 days (0.03376 per 100000): the resulting probability
of death, expected from the reference population and to which
the subject was exposed during the whole 1997, will be 0.03063 
212/365þ0.03376 153/365¼0.03194. The probability of death of
1 year must be added to that of any other year (or fraction of year)
of the follow-up. The observed deaths recorded in the patient
population at the end of the follow-up time and the cumulative
expected probability of death during the corresponding time
obtained from the mortality tables of the general population are
the variables that can be used in both survival calculations and
multivariate analyses.
The Kaplan–Meier method (Kaplan and Meier, 1958) was used
to evaluate survival, and differences were analysed by the Log-rank
test (Peto et al, 1977). The clinical and pathological features that
showed statistically significant prognostic value in univariate
analyses were selected for multivariate analyses. These were
performed by multiple regressions applied to a Cox proportional
hazards model (Cox, 1972). A stepwise selection of factors was
applied to the multiple regressions.
RESULTS
The median length of the follow-up of all patients was 54.6 months
(62.8 for those alive). The range was from 3 to 144 months.
Figure 1 illustrates the survival observed in our series of patients,
the survival expected in a corresponding general reference
population and the relative survival of our patients, computed
from the data of the first two curves. The difference between the
observed and relative survivals is due to the approximately 12% of
deaths expected to occur from causes other than colorectal cancer
(observed/expected deaths: 217/27). Since the number and
distribution along time of these expected deaths may be a
confounding factor in the identification of truly prognostic
determinants, we verified against the relative survival the results
obtained for overall survival in both the univariate and multi-
variate analyses.
Table 2 shows the results of the univariate evaluation of the
prognostic value of all the clinical and pathological factors
considered in relation to both the survival parameters. Most of
the factors that are significantly related to overall survival are also
related to relative survival, though with considerable differences.
The analysis against relative survival seems to reveal an individual
role – not emerging from the study of overall survival – for sex and
neuroinvasion. Tumour size shows no prognostic value with
regards to either survival parameter. The staging systems have the
highest correlation with both overall and relative survival without
a clear prevalence for one system over the others.
All the single factors (i.e., excluding the staging systems) that
demonstrated a significant prognostic value at univariate analysis
were entered into the multivariate evaluation. The final results of
the stepwise selection of variables are reported in Table 3, all the
other factors having been excluded step by step as not contributing
significantly to the model. Three out of the five most powerful
prognostic determinants are the main individual parameters,
which are incorporated in the current staging classifications (depth
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Figure 1 Overall, expected and relative survivals of the 506 patients
with colorectal cancer. Expected survival was that of comparable subjects
of the general reference population, and relative survival was calculated
from the overall and the expected survivals (see Patients and Methods).
Table 2 Results of univariate analysis for overall survival and relative
survival (qualitative data categorised as in Table 1)
Overall survival Relative survival
Variables v
2 P-value v
2 P-value
Sex 0.181 0.6705 21.408 o0.0001
Age 18.379 o0.0001 23.354 o0.0001
Tumour site 0.991 0.3194 0.780 0.3772
Tumour shape 2.680 0.1016 2.179 0.1399
Tumour size 0.843 0.3587 0.209 0.6477
Depth of involvement 22.834 o0.0001 14.782 0.0001
Histological grading 4.053 0.0441 4.885 0.0271
Angioinvasion 1.660 0.1977 1.582 0.2084
Lymphoinvasion 15.258 o0.0001 16.018 o0.0001
Neuroinvasion 3.725 0.0536 4.865 0.0274
Lymphocyte infiltration 0.185 0.6675 0.002 0.9912
Regional node involvement 108.770 o0.0001 82.777 o0.0001
Distant node involvement 4.394 0.0361 5.348 0.0207
Presence of liver metastases 73.541 o0.0001 63.179 o0.0001
Number of liver metastases 73.754 o0.0001 54.246 o0.0001
Extrahepatic metastases 35.407 o0.0001 27.350 o0.0001
Haemoglobin 1.261 0.2614 0.009 0.9261
Serum albumin 0.825 0.3636 0.734 0.3915
Serum CEA 10.965 0.0009 14.263 0.0002
Serum CA19-9 12.808 0.0003 23.058 o0.0001
Dukes’ stages 121.595 o0.0001 96.964 o0.0001
MAC stages 111.716 o0.0001 87.425 o0.0001
TNM stages 120.418 o0.0001 95.893 o0.0001
CA19-9¼carbohydrate antigen 19-9; CEA¼carcinoembryonic antigen.
Table 3 Multivariate analysis for overall survival and relative survival
Overall survival Relative survival
Variables Coefficient P-value Coefficient P-value
Presence of liver metastases 1.209 o0.0001 1.072 o0.0001
Age 0.039 o0.0001  0.054 o0.0001
No. of involved regional nodes 0.115 o0.0001 0.089 o0.0001
Depth of involvement 0.351 0.0313 0.373 0.0092
Postoperative CEA 0.001 0.0925 0.001 0.0321
CEA¼carcinoembryonic antigen. Final results after stepwise selection of the best
clinical parameters.
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sof bowel wall involvement, number of regional lymph nodes
involved and presence of liver metastases). The coefficient of the
fourth factor, age, has an opposite sign according to whether
overall or relative survival is considered. Indeed, age is directly
correlated with overall survival and inversely with relative survival.
The level of CEA is better related to survival than is the level of
CA19-9, although it retains a clearly prognostic role only for
relative survival (while it approaches statistical significance for
overall survival).
Figure 2 illustrates the two different curves of the hazard rate by
age drawn from the coefficients of the multivariate analysis related
to either overall or relative survival. Both these curves are
an expression of the individual role of age when computed
multivariately, that is, after consideration of the other factors
important for survival (they are not crude curves of observed
hazards). It is clear that the role exerted by age on relative survival
is much weaker – although still statistically significant – than that
on overall survival, but shows a clear trend to decrease in the
elderly, in contrast with the marked increase with respect to overall
survival.
Figures 3–5 illustrate the possible integration of CEA levels into
one of the current staging systems (TNM). The survival of the 189
patients of this series presenting with TNM stage II (AþB), of the
176 with stage III (AþBþC) and of the 125 stage IV patients can
be further split according to whether prechemotherapy levels
of CEA were X or o10ngml
 1. The choice of testing the
concentration of 10ngml
 1 as a potential prognostic discriminant
was made for mere illustrative purposes (the analysis of Table 3
does not indicate any distinct threshold level as most suitable for
clinical use, but suggests that the prognostic value of postoperative
CEA is more probably related to the whole distribution of its
levels).
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Figure 2 Different curves of the hazard rate estimated from the
coefficients of the final step of the multivariate analysis in relation to either
the overall (absolute) or the relative (specific) survival. The curve of the
overall survival (thick line) refers to the vertical axis on the right, that of the
relative survival (thin line) refers to the ordinate on the left. The graph
reports the hazards related to the age obtained from multivariate analysis,
(i.e., after consideration of the other factors important for survival – they
are not crude curves of observed hazards). The opposite scales of the two
vertical axes indicate the very different entity of the variation of the hazard
with age, the different slopes of the curve show the opposite role of the
age when multivariately evaluated against overall (absolute) or relative
(specific) survival.
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Figure 3 Relative survival of 189 patients with TNM stage II (AþB)
according to whether their prechemotherapy levels of CEA were X or
o10ngml
 1 (65 and 124, respectively).
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Figure 4 Relative survival of 176 patients with TNM stage III
(AþBþC) according to whether their prechemotherapy levels of CEA
X or o10ngml
 1 (64 and 112, respectively).
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Figure 5 Relative survival of 125 patients with TNM stage IV according
to whether their prechemotherapy levels of CEA X or o10ngml
 1
(39 and 66, respectively).
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sDISCUSSION
Checking prognostic factors evaluated in relation to overall
survival for their significance to relative survival is a way of
recognising and separating what of the patients’ fate depends
strictly on cancer and what depends on the large number of
comorbid conditions that increasingly affect the elderly. Since the
age of the population is increasing and, moreover, the incidence of
colorectal cancer rises with age, it is useful to adjust the overall
survival of these cancer patients according to the expected
mortality from all causes of death. The datum used for this
purpose is the expected mortality in the general population with
exactly the same age, sex and length of observation as for the
group of patients. Note that by this method, sex and age are
considered prognostic factors already present in the general
population, as they undoubtedly are, and can be considered
prognostic factors of the disease under investigation only if the
role usually exerted on the general population is significantly
altered. The relative survival obtained in this way is a very good
estimate of the specific survival, moreover, achieved without the
well-known difficulty of defining the exact causes of death in
retrospective series. This investigation was limited to patients who
underwent local radical resection of a colorectal tumour and all the
data analysed were collected before the start of adjuvant
chemotherapy (or follow-up, if no therapy had to be adminis-
tered).
The study yielded three main results. First, the current staging
systems were confirmed to be best prognosticators in colorectal
cancer, since three out of the five best predictors identified by
multivariate analysis are included in the criteria of the available
staging systems (see Table 3, depth of intestinal wall invasion,
number of regional lymph nodes involved and presence or absence
of liver metastases – as the most frequent type of distant diffusion).
The superiority of the staging models over any other individual
factor is also evident from the comparative evaluation of the w
2-
values of the univariate analysis reported in Table 2. Thus, the
pivotal prognostic role of current staging systems in colorectal
cancer remains undisputed after computation of relative survival.
Second, the true impact of age per se on the chance of surviving
the direct effects of colorectal cancer has been clarified. When
overall survival of patients with colorectal cancer is considered,
age has the same strong and unfavourable prognostic significance
as observed in most neoplastic diseases, being greater as age
increases. In contrast, when relative survival is considered, age
shows a weak, but statistically significant, favourable effect – a sort
of mild protection. In other words, the number of unexpected
deaths (i.e., those due to cancer) that can be multivariately
ascribed to age, decreases slowly, but significantly, as age
increases. When studying a cancer of the elderly, if analyses are
restricted to overall survival, a considerable amount of mortality
from other causes (e.g., infections, cardiovascular diseases,
hypertension and diabetes) will be wrongly attributed to the
tumour. Thus, different age ranges of the populations studied, or
different age groups chosen for the analyses, together with a
variable prevalence of nonneoplastic diseases in the evaluated
series, can explain the discordant results in the scientific literature
regarding age and colorectal cancer. Indeed, different authors have
found an independent unfavourable effect of increasing age
(Korenaga et al, 1991; Gasser et al, 1992; Crocetti et al, 1996;
D’Eredita et al, 1996; Wolters et al, 1996; Payne and Meyer, 1997;
Tominaga et al, 1997; Heys et al, 1998; Lagautriere et al, 1998;
Fietkau et al, 2004; Munemoto et al, 2004), of the youngest and
oldest age ranges, indifferently (Chung et al, 1998; Cerottini et al,
1999; Massacesi et al, 2002) or even of young age (Cai et al, 2005),
while other investigators were not able to demonstrate any
prognostic effect at all (Ponz de Leon et al, 1992; Wang et al,
2000; Mitry et al, 2004; Latkauskas et al, 2005). Only Janssen-
Heijnen et al (2005) evaluated relative survival of patients with
several cancers, utilising data from the Southern Netherlands
Cancer Registry. They found that the 5-year relative survival of
patients with colon cancer was slightly better in subjects X70 years
of age than in those o70 years old, whereas it was not affected by
age in patients with indolent non-Hodgkin’s lymphomas and
prostate cancer, and was clearly lower in older patients with other
cancers. The prevalence of comorbidity, which is claimed as a
reason for less aggressive treatment in the elderly, can explain the
poorer survival of older patients with most types of cancer, but
seems to be inadequate for those with colon cancer. Indeed, why
and how age exerts a mild protective effect on specific mortality of
colorectal cancer is not clear. According to the most probable
hypothesis, the tumour might progress more slowly in older
patients. This idea is popular but is still debated and so far
unproven. The results presented here offer indirect support for this
hypothesis, but not evidence. Some genetic alterations, such as that
of the promoter of the MDM2 oncogene, are able to modify the age
of onset of colorectal cancer and probably differentiate prognosis
(Menin et al, 2006). Alternatively, adjuvant therapies may be more
effective in the elderly, although this seems a rather untenable
hypothesis. Certainly, age should no longer be considered the only,
direct criterion for evaluating the indication of postsurgical
therapies and for choosing the type of chemotherapy. Besides
age, more attention should be paid to the presence of comorbid
conditions, chronic diseases and functional disabilities that are
frequent causes of complications and death in the elderly. A
number of questionnaires have been devised with the purpose of
selecting frail subjects in older cohorts (Repetto et al, 2001;
Matthes et al, 2004) and probably a multiparameter evaluation
should replace age alone in the selection of candidates for
chemotherapy.
The third main result of this study is the independent predictive
value of postsurgery CEA levels. In our multivariate analysis the
postoperative level of CEA replaced that of postoperative CA19-9 as
the major determinant (with a statistically relevant weight for
relative survival), although the two had apparently similar
prognostic roles at univariate analysis. In most of the previous
studies aimed at evaluating the implications of CEA levels for
staging and prognosis, the serum concentration of CEA was
evaluated preoperatively and, despite some conflicting results, the
majority of them showed a direct prognostic value (a nice review on
this topic is available in a recent paper by Chen et al, 2005). Since
the CEA level seems to roughly reflect the tumour burden and/or
diffusion (Wanebo et al, 1978), its preoperative evaluation might
offer a crude estimate of neoplastic spread and, thus, of the
probable difficulty of achieving successful radical resection. A drop
in CEA levels after the resection is considered a favourable
indicator of the completeness of the surgical excision (Herrera et al,
1976), although CEA concentration is generally regarded as more
sensitive for hepatic and retroperitoneal metastases than for local
recurrence or peritoneal and pulmonary metastases (Crawford
et al, 2003). According to Kanellos et al (2006c), the measurement
of the CEA level in the blood intraoperatively taken from the
mesenteric vein offers some advantage, as both indicator of hepatic
metastases and predictor of 5-year survival. The same investigators
also found a higher recurrence rate in patients with both high CEA
levels and positive citology in peritoneal washings taken at the
beginning of surgery (Kanellos et al, 2003, 2006b). Several patients
in the present series were referred to our unit from a neighbouring
hospital with preoperative CEA often not technically comparable or
even not assessed. However, we know that apart from cases with
documented distant metastases (stage IV), some patients have CEA
levels higher than normal after putatively radical operations,
without any instrumental macroscopic evidence of persisting local
residual disease or distant spread. Since the half-life of CEA serum
level has been calculated to be a few days – from 3.0 (Rapellino
et al, 1994) to 4.3 (Ito et al, 2002) or 6.2 (Choi and Min, 1997) – our
evaluation at a mean interval of 42 days after surgery – and rarely
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safter less than 4 weeks – seems able to reliably reflect the presence
of occult spread of the disease. In such cases, the clinical problem is
whether to plan adjuvant therapy according to the TNM stage only
or whether to consider also the altered marker value as an
important worsening factor.
The clinical importance of CEA is clear at whatever time it is
assessed along the clinical course of patients with colorectal
cancer, but the demonstration of it having a prognostic role also
postoperatively would be interesting for deciding treatment
strategies. Besides providing a serologic indication of how radical
the resection has been, in addition to the mandatory microscopic
inspections by the histopathologists – it could offer further
information to guide the choice of subsequent treatment. This
decisional step is becoming ever more critical given the large
number of available adjuvant chemotherapy regimens, with
selective indications and different intensities and toxicities. Since
the ultimate fate of the patients with colorectal cancer is related to
three main factors (initial tumour stage, radicality of the surgical
resection and effectiveness of adjuvant therapy – when necessary),
the postoperative evaluation of the CEA level (after 5–6 weeks), in
that it allows a reliable check of the last two factors, can be at least
as important as the preoperative one. Thus, we fully agree with the
proposal of the American Joint Committee on Cancer (Compton
et al, 2000), which recommends the inclusion of CEA into the TNM
classification (with the following suggested notations for any stage:
CX, CEA not assessed; C0, CEA not elevated; and C1, CEA
elevated). We only wonder whether the measurements of CEA for
such a categorisation should be more properly performed at a
suitable interval after surgery (we suggest 5–6 weeks) – instead of
or in addition to before surgery.
In conclusion, our study of the relative survival in a population
of patients who had undergone radical resection of colorectal
cancer fully confirms the adequacy of the individual clinicopatho-
logical factors, which are the basis of the current Dukes’, modified
Astler–Coller and TNM staging classifications. The results
presented offer a possible explanation for the conflicting reports
on the prognostic role of age and, finally, show the true prognostic
value – strictly related to cancer – of the CEA level, with particular
emphasis on its postoperative assessment.
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